CIS-014 Evaluation of Performance and Safety of aScope 4 Cysto

  • Research type

    Research Study

  • Full title

    Clinical investigation to evaluate the performance and safety of Ambu® aScope™ 4 Cysto and aView™ Urologia for flexible cystoscopy

  • IRAS ID

    278634

  • Contact name

    Jacob Mark Patterson

  • Contact email

    jake.patterson@nhs.net

  • Sponsor organisation

    Ambu AS

  • Clinicaltrials.gov Identifier

    NCT04192474

  • Duration of Study in the UK

    0 years, 2 months, 7 days

  • Research summary

    The purpose of this study is to investigate the performance and safety of a new cystoscope, called aScope 4 Cysto, for the use in flexible cystoscopy and if the aScope 4 Cysto performs as well as other routinely used cystoscopes for diagnostic and procedural purposes. The main difference between currently available cystoscopes used at the hospital and the investigational cystoscope is that the aScope 4 Cysto is developed for single use. During the cystoscopy procedure, the aScope 4 Cysto is used for a diagnosis of a condition of the bladder and urethra, followed by a procedure in 50% of the cases. For a procedure, an additional tool will be guided through the aScope 4 Cysto. The additional tool will be able to take a piece of tissue (biopsy), remove damaged tissue, remove a stent or give a botox injection. The study includes screening, consent process, basic medical examination, 30 minutes cystoscopy procedure and a follow-up call after 7 days. A total of 80 patients are planned for the study.

    The performance of the aScope 4
    Cysto will be evaluated via a phone call
    seven days after the procedure.
    During the call the Investigator or a
    member of their team will complete a
    questionnaire to provide a qualitative
    assessment of the participant’s
    experiences. The results obtained will
    be reviewed and analysed as per the
    statistical plan for the study.

  • REC name

    West of Scotland REC 4

  • REC reference

    20/WS/0088

  • Date of REC Opinion

    19 Aug 2020

  • REC opinion

    Further Information Favourable Opinion